Title: The Safe Administration of Rapid Rituximab Infusion: An Evidence-Based Approach

Name: Siew Ping Lang

ID: 1216095

School: The Joanna Briggs Institute, Faculty of Health Science

Date: 16 July 2012

This thesis is submitted in total fulfillment of the requirements for the degree of Doctor of Philosophy
CHAPTER 1. INTRODUCTION TO THE STUDY .......................................................... 14

Researcher’s Clinical Experience in this Field of Study ........................................... 14

Emergence of Monoclonal Antibody Therapy for Cancer Treatment ....................... 15

Side Effects of Cancer Treatment ............................................................................. 15

Prevalence and Incidence of non-Hodgkin Lymphoma ........................................... 16

Rituximab in Chemotherapy Regimen for non-Hodgkin Lymphoma ....................... 16

Administration Rate of Rituximab ........................................................................... 17

Duration of Rituximab Therapy ................................................................................. 19

Clinical Observation of a Patient’s Tolerance of Rituximab ..................................... 19

The Clinical Burden of Rituximab Infusion ............................................................... 20

Global Interest in Seeking Alternative Administration Rates for Rituximab Infusion ... 21

CHAPTER 2. BACKGROUND TO THE STUDY ....................................................... 22

Theoretical Framework ............................................................................................. 22

The Historical Emergence of Evidence-based Health Care (EBHC) ......................... 22

The Joanna Briggs Institute (JBI) Model of EBHC .................................................... 22

Framework of the JBI Model ................................................................................... 23
Literature Review .............................................................................................................................25
Part 1: Historical background of Rituximab ............................................................................... 25
Part 2: Adverse Drug Events of Rituximab Infusion ................................................................... 42
Part 3: Predictors of Rituximab Induced Adverse Drug Events .................................................. 47

CHAPTER 3. STUDY METHODS ..................................................................................... 54

Phase 1: The Systematic review ................................................................................................. 54
The Systematic Review Protocol ................................................................................................. 54
Background to the Review ........................................................................................................... 54
Significance of the Systematic Review ...................................................................................... 55
Justification of the Population of Interest for the Systematic Review ........................................ 56
Justification of Outcome Measure for the Systematic Review ................................................... 57
Potential Confounding factor for Outcome measure ................................................................. 57
Justification of Intervention of Interest for the Systematic Review .......................................... 57
Justification Types of Study Included in the Systematic Review ............................................. 59
Review objective ......................................................................................................................... 59
Review questions ......................................................................................................................... 59
Criteria for considering studies for this review ........................................................................ 60
Review methods .......................................................................................................................... 62
Assessment of Methodological Quality ..................................................................................... 65

Phase 2: Retrospective Cohort Study ...................................................................................... 67
Background to the Retrospective Cohort Study ........................................................................ 67
Study Objectives ......................................................................................................................... 69
Specific Aims of the Study .......................................................................................................... 69
Research question ....................................................................................................................... 69
Hypotheses .................................................................................................................................. 70
Operational definition of terms ................................................................................................. 70
Study Design ............................................................................................................................... 72
Sampling ............................................................................................................................................ 73
Sample size calculation ...................................................................................................................... 74
Study Protocol ................................................................................................................................... 74
Data management ............................................................................................................................. 75
Ethics and Human Subjects Issues ..................................................................................................... 76
Statistical Analysis ......................................................................................................................... 76

CHAPTER 4. RESULTS FROM PHASE 1: SYSTEMATIC REVIEW ............................................ 79

Description of studies ...................................................................................................................... 79

Methodological quality ..................................................................................................................... 81

Descriptive Analysis of Results ......................................................................................................... 83

Summary of Non-Hodgkin Lymphoma patients in 60-minute Rapid Rituximab Regimen ............ 96

Summary of Chronic Lymphocytic Leukemia patients in 90 and 60-minute Rapid Rituximab Regimen ................................................................................................................................. 96

CHAPTER 5. RESULTS FROM PHASE 2: RETROSPECTIVE COHORT STUDY .... 98

Patients’ Characteristics .................................................................................................................. 98

Age .................................................................................................................................................... 98
Gender ............................................................................................................................................... 98
Diagnosis .......................................................................................................................................... 99
Stage of Disease ............................................................................................................................... 99
Presence of Cardiac and Lung Disease as Co-morbidities .............................................................. 100
Type of Treatment ......................................................................................................................... 103
Body Surface Area .......................................................................................................................... 103
Premedication .................................................................................................................................. 104
Blood Count Level ........................................................................................................................... 105
Frequency of Adverse Drug Events ................................. 108
Type of Adverse Drug Events ........................................ 108
Severity of Adverse Drug Events ................................. 110
Timing of Occurrence of Adverse Drug Events ............ 112
Occurrence of Adverse Drug Events in Specific Cycles .... 115

Univariate Analysis using Log Binomial Generalised Estimating Equations .......... 117

Age ........................................................................ 117
Gender .................................................................... 117
Diagnosis .................................................................. 117
Stage of disease ....................................................... 118
Presence of cardiac or lung morbidity ....................... 118
Number of courses .................................................. 120
Number of cycles ..................................................... 120
Type of treatment .................................................... 120
Dosage prescription based on body surface area .......... 120
Use of corticosteroids as premedication .................. 121
Use of antipyretics as premedication ....................... 121
Use of antihistamines as premedication ................. 121
Total white blood cell counts .................................. 121
Lymphocyte counts ................................................ 121
Lactate dehydrogenase level ................................... 122
Absolute neutrophil count ...................................... 122


Age ........................................................................ 124
Gender .................................................................... 124
Diagnosis .................................................................. 124
Stage of disease ................................................................. 125
Presence of cardiac or lung morbidity ......................................................... 125
Number of courses ...................................................................... 127
Number of cycles ........................................................................ 127
Type of treatment ......................................................................... 127
Dosage prescription based on body surface area ................................. 127
Use of corticosteroids as premedication ........................................... 128
Use of antipyretics as premedication ............................................... 128
Use of antihistamines as premedication ............................................ 128
Total white blood cell counts .......................................................... 128
Lymphocyte counts ....................................................................... 128
Lactate dehydrogenase level .............................................................. 128
Absolute neutrophil counts ................................................................. 129

Multivariate Analysis Model Occurrence of Adverse drug events .................................................. 131
Multivariate Analysis Model Count of Adverse drug events ......................................................... 132
Univariate Analysis of Severity of Adverse Drug Events ............................................................... 133
Age ..................................................................................... 133
Gender .................................................................................... 133
Diagnosis .................................................................................. 133
Stage of disease ......................................................................... 133
Presence of cardiac or lung morbidity ............................................. 133
Number of courses .................................................................... 135
Number of cycles ........................................................................ 135
Type of treatment ....................................................................... 135
Dosage prescription based on body surface area ............................. 135
Use of corticosteroids as premedication .......................................... 135
Use of antipyretics as premedication .............................................. 136
Use of antihistamines as premedication ................................................................. 136
Total white blood cell counts .................................................................................. 136
Lymphocyte counts ................................................................................................... 136
Lactate dehydrogenase level .................................................................................. 136

Management of adverse drug events ................................................................. 138

CHAPTER 6. DISCUSSION OF THE PHASE 1 AND PHASE 2 FINDINGS .......... 140

Phase 1 Study: Systematic Review ........................................................................ 140
Meta-analysis of adverse drug events among non-Hodgkin Lymphoma patients 140
Diagnoses included in the systematic review ......................................................... 140
Assessment of publication bias .............................................................................. 141
Narrative Summary for Chronic Lymphocytic Leukemia ...................................... 142
Premedication used prior to rapid Rituximab infusion ........................................... 142
Instrument for assessing adverse drug events ...................................................... 142
Methodological quality of included studies .......................................................... 143
The Limitations of the Phase 1 Systematic Review ................................................. 144
Implications for Practice from the Phase 1 Systematic Review ............................... 145
Implications for Research from the Phase 1 Systematic Review ............................. 145

Phase 2 study: Retrospective Cohort Study .......................................................... 146
Using binary versus count data in outcome measures .......................................... 146
High lymphocyte counts as a predictor of occurrence of adverse drug events from rapid Rituximab infusion ................................................................. 147
Applicability of identifying high lymphocyte count as a predictor of occurrence of adverse drug events ................................................................. 148
Frequency and type of adverse drug event ............................................................ 148
Pattern of occurrence of adverse drug events ...................................................... 149
Management of adverse drug events according to the severity of adverse drug events 150
Age ................................................................................................................................................... 151
Gender ............................................................................................................................................... 151
Diagnosis ......................................................................................................................................... 152
Stage of disease ............................................................................................................................... 153
Presence of cardiac or lung disease ............................................................................................. 154
Type of treatment .......................................................................................................................... 154
Prescription dosage based on body surface area ........................................................................ 155
Premedication ................................................................................................................................. 155
Blood counts .................................................................................................................................... 156
Course and cycle ............................................................................................................................ 156
Severity of adverse drug event ....................................................................................................... 157
Management of adverse drug events .............................................................................................. 158

CHAPTER 7: DEVELOPMENT OF CLINICAL PRACTICE GUIDANCE ............... 159

Standard 1 Establishing transparency ............................................................................................ 159
Standard 2 Management of conflict of interest ............................................................................ 159
Standard 3 Guideline development group composition ............................................................... 160
Standard 4 Systematic review intersection .................................................................................. 160
Standard 5 Establishing evidence foundations and rating strength and recommendation ....... 160
Standard 6 Articulation of recommendation ............................................................................... 160
Standard 7 External review ........................................................................................................... 160
Standard 8 Updating ..................................................................................................................... 160
Draft Administration guideline of rapid Rituximab infusion at 90 minutes and management of its infusion-related adverse drug events ................................................................. 161
Abstract
The goal of this study was to approach a global clinical issue that is imperative using an evidence-based approach to the investigation of the rapid administration of rituximab infusions for non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). This study focused on an evidence-based approach to improving patient safety, drawing on the Joanna Briggs Institute’s model of evidence-based health care with its particular emphasis on evidence synthesis, evidence generation and evidence transfer.

The study consists of two central phases. The first phase is a comprehensive systematic review (CSR), which informed the design of a subsequent primary study that constitutes the second phase.

The specific systematic review question was: “How safe is it to administer rituximab rapidly for NHL and CLL patients?” The objective was to identify and synthesise the existing published and unpublished literature on the use of rapid rituximab infusion as an alternative infusion rate and its safety. The systematic review found that rapid rituximab infusion is not safe for chronic lymphocytic leukemia (CLL) patients yet it is safe for non-Hodgkin Lymphoma (NHL) patients. However, there was insufficient evidence to address other aspects of clinical concern related to the safe administration of the rapid infusion of rituximab. Therefore, a retrospective cohort study was conducted in Royal Adelaide Hospital (RAH), South Australia to elicit evidence that informs our current understanding of rapid rituximab infusion. The findings of the study identified high lymphocyte counts as the sole predictor of the occurrence and frequency of adverse drug events such as hypotension, hot flushes and itchiness. The evidence generated from the systematic review and primary study was transferred into a clinical guideline on administering rapid rituximab infusion safely and a pamphlet
for patients who are receiving the rapid regimen was developed.
Declaration

NAME: Siew Ping Lang               PROGRAM: Doctor of Philosophy

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holder/s of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the university to restrict access for a period of time.

SIGNATURE………………………………DATE:……………………………………
Acknowledgments

I would like to acknowledge and extend my heartfelt gratitude to the following persons who have made the completion of this thesis possible:

My principal supervisor, Professor Alan Pearson for his vital encouragement, guidance, and support from the beginning to the final level enabled me to complete the PhD.

My co-supervisor, Professor Dorothy Keefe for her expertise in oncology medicine and assistance in conducting the research study in Royal Adelaide Hospital.

My co-supervisor, Dr Timothy Schultz for his expertise and guidance in statistical matters.

My former supervisor, Dr Christina Hagger for her constant support and encouragement.

The statistician, Mr Thomas Sullivan, for assisting in data analysis

The CEO of National University Hospital, Mr Joe Sim and the Director of Nursing, Mrs Lee Siu Yin for their endorsement of the PhD’s scholarship.

The Head of Oncology Nursing, Dr Emily Ang for her help in making my PhD journey possible.

SAS for accepting me into their fellowship program and granting me one year free access to the SAS statistical software program.

All Joanna Briggs Institute, Library, Research Education and Development and Oncology Department faculty members and staff for providing practical help in the completion of this PhD.

Most especially to my family and friends.

And to God, who makes all things possible.